Larazotide is a very short peptide that researchers study for one job. That job is helping the lining of the gut keep the tiny gaps between its cells closed. These gaps are guarded by “tight junctions,” and larazotide is mostly studied in research on celiac disease.
This guide explains what larazotide is, how it is thought to work, what the studies found, and how it compares with other gut peptides. It describes published research only and is not advice for any person.
Many websites mix lab findings, small studies and health promises into one story. This guide keeps them apart and says clearly where the evidence stops.
What Is Larazotide
A peptide is a short chain of building blocks called amino acids. Think of it as a very small piece of a protein. Larazotide has just eight of them. Here is the quick profile.
| Item | Plain answer |
|---|---|
| What it is | A short, lab-made peptide with 8 amino acids |
| Also called | Larazotide acetate, or AT-1001 in older studies |
| Where the idea came from | A toxin made by the bacteria that cause cholera |
| What it is studied for | Keeping the gaps between gut cells closed |
| Main research area | Celiac disease |
| How the trials delivered it | By mouth, in a coated capsule |
| Sold as a medicine | No, not anywhere in the world |
Picture the lining of your gut as a tiled floor. Things can cross it in two ways. They can pass through the tiles, which is how most nutrients get absorbed. Or they can slip through the gaps between the tiles. Tight junctions are the grout that keeps those gaps shut.
The idea began with a germ. In the early 1990s, researchers found that the bacteria that cause cholera make a toxin that pries those gaps open. They called it Zot. In 2000, the same group reported that the human body makes a similar signal, and they named it zonulin. Larazotide was developed from this work. It is meant to block the “open the gaps” signal, not send it.
Key point. Larazotide is studied as a possible grout keeper for the gut lining. It is made in a lab and has never been sold as a medicine.
How Does Larazotide Work?
Here is the leading idea, step by step.
- A trigger starts the process. One studied trigger is gluten, a protein in wheat, barley and rye, in people with celiac disease.
- The gut cells release more zonulin.
- Zonulin sends a signal inside the cells, and the scaffolding that holds the grout in place shifts.
- The gaps between the cells open a little wider.
- Larazotide is thought to interrupt the signal, so the grout stays where it is.
Researchers check this in a dish. They grow a layer of gut cells and measure how well it holds back a tiny electrical current. A tight layer holds it back well, and a leaky layer does not. In the main lab paper on larazotide, published in 2012, larazotide was reported to reduce the drop in that measurement after the cells met a trigger. The proteins that make up the grout also stayed closer to their normal spots.
Larazotide is also unusual in how it was delivered. Most peptides are broken down quickly by digestive juices. Larazotide works on the inner face of the gut lining, so the studies used a coated capsule designed to release it further down the small intestine. Published reports say very little of it reaches the blood.
Key point. Scientists still do not fully agree on exactly where larazotide attaches. That is why this is called a proposed mechanism, which means a leading idea and not a finished answer.
What Potential Benefits Does Larazotide Research Examine?
Almost all of the published work asks one question. Could helping the gut barrier matter in celiac disease? In celiac disease, eating gluten sets off an immune reaction that damages the gut lining. The usual approach is a strict gluten-free diet, but some people still have symptoms on it. Researchers wanted to know whether a barrier-supporting compound could make a difference for that group.
The trials looked at three kinds of measures:
- Symptom scores from standard questionnaires.
- A leak test, a sugar test that estimates how much passes through the gut wall.
- A blood marker, an antibody that rises after gluten exposure in celiac disease.
Earlier lab work also tested larazotide as a general protector of the gut barrier, using injury and inflammation models. Those studies were smaller and have been repeated less often.
Key point. Some websites claim larazotide helps with skin, mood, joints, muscles, type 1 diabetes, Crohn’s disease or multiple sclerosis. No published larazotide trial backs up those claims.
What Does the Research Actually Show?
Larazotide is one of the few peptides in this area with a real clinical trial history. Here is what was published. Nothing in it is a recommendation for any person.
| Year | Study | Who took part | What was reported |
|---|---|---|---|
| 2007 | Early safety study | People with celiac disease | Looked at safety and how the body handles single amounts |
| 2012 | Gluten challenge | A small group with celiac disease | Smaller gluten-related changes in the leak test and symptoms than placebo |
| 2013 | Gluten challenge | 184 people, 6 weeks of daily gluten | Leak test no different from placebo. Symptom scores lower in one of three groups. Blood marker rose less in all three |
| 2015 | 12-week study | 342 adults with symptoms despite a gluten-free diet | The lowest of three amounts met the main symptom goal. Higher amounts did not do better |
| 2022 | Phase 3 trial | A large late-stage group | Stopped after an interim review found it unlikely to meet its main goal |
A placebo is a pill with no active ingredient, used for comparison. A gluten challenge means people with celiac disease eat a measured amount of gluten under supervision. The 2013 authors called their study early and exploratory.
The 2015 result is surprising, since more is usually expected to do better. The Phase 3 stop does not mean research on the gut barrier is a dead end. It shows how hard it is to turn a clean result in a dish into a steady result in people.
Measuring is part of the problem. In 2018, a group reported that a popular test kit sold as a “zonulin test” did not detect zonulin and picked up a different protein instead. A 2019 study reached a similar careful conclusion. The different ways of measuring gut leakiness also do not always agree with each other. “Leaky gut” is common online, but it is not a medical diagnosis.
Key point. The results were mixed. Some of that may come from the compound, and some may come from how hard the gut barrier is to measure.
What Side Effects Were Reported in Larazotide Studies?
These are signals from published studies and are not advice. In the gluten challenge and symptom studies, side effects were generally similar in rate between the larazotide groups and the placebo groups. This fits with the idea that the compound stays mostly inside the gut.
Summaries and reviews mention headache and mild stomach complaints, such as nausea or belly discomfort. The exact types and rates differ from study to study, so they should be checked in the original papers.
The limits matter as much as the findings. The studies lasted from a few weeks up to twelve weeks, so nothing is known about long-term safety. The people in them were adults with celiac disease, so the studies say little about anyone else.
Key point. Some commercial websites list side effects that do not appear in any study paper. When a list has no source, treat it as unconfirmed.
How Does Larazotide Compare to Other Gut Peptides?
These peptides work on different parts of the picture, so it helps to think of them as separate lanes.
| Peptide | Size | Studied for | Lane |
|---|---|---|---|
| Larazotide | 8 amino acids | Keeping the gaps between gut cells closed | The gate |
| KPV | 3 amino acids | Calming inflammation signals inside gut cells | The alarm |
| BPC-157 | 15 amino acids | Tissue damage and healing in lab models | Repair |
| Thymosin alpha 1 | A longer peptide linked to the thymus | How immune responses are shaped | Immune tone |
Want to read more about each one?
- The KPV peptide research guide covers the alarm lane.
- The BPC-157 mechanism overview and BPC-157 benefits research cover the repair lane.
- The thymosin alpha 1 research summary covers the immune lane.
Handling, Storage and Research Use
In a laboratory, larazotide usually arrives as a freeze-dried powder in a sealed vial. Like other peptides, it is sensitive to moisture and heat, so labs keep it sealed, dry and cold and follow the supplier’s storage instructions. Larazotide is sold both as an acetate and as a trifluoroacetate salt. These are not interchangeable in every experiment, so check which one the supplier lists.
Look for three things on any research peptide:
- Purity, which tells you how much of the powder is the actual compound. It is usually measured by a lab method called HPLC and shown as a percentage on a certificate of analysis.
- Identity, which confirms the molecule is the right one. This is usually done by mass spectrometry, which weighs the molecule and compares it with the expected weight.
- A batch number on the vial that matches the certificate, which makes the results traceable.
This site’s research use disclaimer states that its products are supplied with certificates of analysis, and the FAQ describes independent third-party testing of each batch.
Good lab habits include labeling every vial, logging when each container was opened, and writing down the concentration and liquid used for any solution. The concentration calculator can check that math for a given vial amount and liquid volume. Research compounds are for qualified laboratory work only. Anyone with questions about their health should speak with a medical professional. You can browse the research peptide catalog to see what is currently listed.
FAQ
What is larazotide?
A short, lab-made peptide with eight amino acids. It is studied for its effect on the seals between cells in the gut lining and was developed from research on a bacterial toxin that opens those seals.
What does larazotide acetate mean?
Acetate is just the form of the powder. Papers use “larazotide” and “larazotide acetate” to mean the same compound.
Is larazotide the same as zonulin?
No. Zonulin is a protein the body makes, and it is thought to open the gaps between gut cells. Larazotide is a lab-made peptide thought to block that signal.
How is larazotide different from KPV?
KPV is studied for calming inflammation signals inside cells. Larazotide is studied for the seals between cells.
Has larazotide completed clinical trials?
Several early and mid-stage trials were published, with mixed results. A Phase 3 trial was stopped in mid-2022. Larazotide has not been sold as a medicine.
Were side effects reported in the studies?
Side effects were generally similar to placebo, and they included headache and mild stomach complaints. The studies were short, so long-term safety is unknown.
Is larazotide only studied in celiac disease?
Most of the published trials are in celiac disease. Earlier lab work looked at it as a general gut barrier protector, but those studies are smaller.
Key Takeaways
- Larazotide is a short, lab-made peptide studied for its effect on the seals between gut cells.
- It is thought to block a signal that opens those seals, though scientists have not fully settled exactly how.
- Trials in celiac disease gave mixed results, and a Phase 3 trial was stopped in mid-2022.
- Side effects were generally similar to placebo in short studies, and long-term safety is unknown.
- Claims about skin, mood, joints or other conditions have no larazotide trial behind them.
- Larazotide is studied for the gate of the gut, which is different from KPV, BPC-157 and thymosin alpha 1.
Research Use Disclaimer
This content is provided for Research Use Only (RUO). The compounds discussed are not drugs, dietary supplements, foods, or cosmetics, and are not intended for human or animal consumption, diagnostic use, or therapeutic use of any kind. They have not been evaluated by the FDA for safety or efficacy in humans. Any research use must be conducted by qualified professionals in a controlled laboratory environment, in accordance with all applicable institutional, local, and federal regulations.
Sources
- Fasano A, Baudry B, Pumplin DW, et al. Vibrio cholerae produces a second enterotoxin, which affects intestinal tight junctions. Proc Natl Acad Sci USA. 1991.
- Wang W, Uzzau S, Goldblum SE, Fasano A. Human zonulin, a potential modulator of intestinal tight junctions. J Cell Sci. 2000.
- Tripathi A, Lammers KM, Goldblum S, et al. Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2. Proc Natl Acad Sci USA. 2009.
- Fasano A. Zonulin and its regulation of intestinal barrier function, the biological door to inflammation, autoimmunity, and cancer. Physiol Rev. 2011.
- Lammers KM, Lu R, Brownley J, et al. Gliadin induces an increase in intestinal permeability and zonulin release by binding to the chemokine receptor CXCR3. Gastroenterology. 2008.
- Gopalakrishnan S, Durai M, Kitchens K, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012.
- Paterson BM, Lammers KM, Arrieta MC, Fasano A, Meddings JB. The safety, tolerance, pharmacokinetic and pharmacodynamic effects of single doses of AT-1001 in coeliac disease subjects, a proof of concept study. Aliment Pharmacol Ther. 2007.
- Leffler DA, Kelly CP, Abdallah HZ, et al. A randomized, double-blind study of larazotide acetate to prevent the activation of celiac disease during gluten challenge. Am J Gastroenterol. 2012.
- Kelly CP, Green PH, Murray JA, Dimarino A, Colatrella A, Leffler DA, et al. Larazotide acetate in patients with coeliac disease undergoing a gluten challenge, a randomised placebo-controlled study. Aliment Pharmacol Ther. 2013;37(2):252-262.
- Leffler DA, Kelly CP, Green PH, et al. Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet, a randomized controlled trial. Gastroenterology. 2015.
- Scheffler L, Crane A, Heyne H, et al. Widely used commercial ELISA does not detect precursor of haptoglobin2, but recognizes properdin as a potential second member of the zonulin family. Front Endocrinol. 2018.
- Ajamian M, Steer D, Rosella G, Gibson PR. Serum zonulin as a marker of intestinal mucosal barrier function, may not be what it seems. PLoS One. 2019.
- Camilleri M. Leaky gut, mechanisms, measurement and clinical implications in humans. Gut. 2019.
Explore the research peptide catalog for laboratory compounds, see the injury and recovery category for related research compounds, and read more gut and immune research in the Health & Performance blog category.
